Published in Blood Weekly, October 30th, 2003
"Allogeneic hematopoietic chimerism leading to central tolerance has significant therapeutic potential," scientists in the United States noted. However, the "realization of that potential has been impeded by the need for myeloablative conditioning of the host and development of graft-versus-host disease (GVHD)."
"To surmount these impediments," E. Seung and colleagues at the University of Massachusetts "adapted a costimulation blockade-based protocol developed for solid organ transplantation for use in stem-cell...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.